Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel. Overall survival was significantly improved with pertuzumab in an interim analysis without the median being reached. We report final prespecified overall survival results with a median follow-up of 50 months. METHODS: We randomly assigned patients with metastatic breast cancer who had not received previous chemotherapy or anti-HER2 therapy for their metastatic disease to receive the pertuzumab combination or the placebo combination. The secondary end points of overall survival, investigator-assessed progression-free survival, independently assessed duration of response, and safety are reported. Sensitivity analyses were adjusted for patients who crossed over from placebo to pertuzumab after the interim analysis. RESULTS: The median overall survival was 56.5 months (95% confidence interval [CI], 49.3 to not reached) in the group receiving the pertuzumab combination, as compared with 40.8 months (95% CI, 35.8 to 48.3) in the group receiving the placebo combination (hazard ratio favoring the pertuzumab group, 0.68; 95% CI, 0.56 to 0.84; P<0.001), a difference of 15.7 months. This analysis was not adjusted for crossover to the pertuzumab group and is therefore conservative. Results of sensitivity analyses after adjustment for crossover were consistent. Median progression-free survival as assessed by investigators improved by 6.3 months in the pertuzumab group (hazard ratio, 0.68; 95% CI, 0.58 to 0.80). Pertuzumab extended the median duration of response by 7.7 months, as independently assessed. Most adverse events occurred during the administration of docetaxel in the two groups, with long-term cardiac safety maintained. CONCLUSIONS: In patients with HER2-positive metastatic breast cancer, the addition of pertuzumab to trastuzumab and docetaxel, as compared with the addition of placebo, significantly improved the median overall survival to 56.5 months and extended the results of previous analyses showing the efficacy of this drug combination. (Funded by F. Hoffmann-La Roche and Genentech; CLEOPATRA ClinicalTrials.gov number, NCT00567190.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“the safety and efficacy profiles for SC trastuzumab in combination with IV pertuzumab and docetaxel as a first-line treatment for patients with HER2-positive MBC in the MetaPHER study (NCT02402712) was found to be consistent with those observed for IV trastuzumab in combination with IV pertuzumab and docetaxel in the CLEOPATRA study (NCT00567190) [21, 35–38].”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citationPertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Self-citationGianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.-A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,374
Self-citationSmith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4451 · Cited by 1,636
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144
Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Self-citationvon Minckwitz, G., du Bois, A., Schmidt, M., Maass, N., Cufer, T., de Jongh, F. E., Maartense, E., Zielinski, C., Kaufmann, M., Bauer, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6618 · Cited by 676
Baselga, J., Gelmon, K. A., Verma, S., Wardley, A., Conte, P., Miles, D., Bianchi, G., Cortes, J., McNally, V. A., Ross, G. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2024 · Cited by 643
Self-citation
Cited by
Items 801–900 of 1,001
A review of systemic anticancer therapy in disease palliation
Usborne, C., & Mullard, A. P. (2017) · British Medical Bulletin · doi:10.1093/bmb/ldx045 · Cited by 17
Williamson, T. J., Love, S. M., DeHart, J. N. C., Jorge-Miller, A., Eshraghi, L., Ortner, H. C., & Stanton, A. L. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4823-x · Cited by 18
Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives
Soto‐Pérez‐de‐Celis, E., Loh, K. P., Baldini, C., Battisti, N. M. L., Chávarri-Guerra, Y., de Glas, N. A., Hsu, T., & Hurria, A. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1520838 · Cited by 19
Costa, R. L. B., Zaman, S., Sharpe, S. C., Helenowski, I., Shaw, C., Han, H. S., Soliman, H. H., & Czerniecki, B. J. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s188925 · Cited by 17
Liu, J., Wu, X., Lin, L., Pan, H., Wang, Y., Li, Y., Zhao, Y., & Wang, Z. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.03.009 · Cited by 19
Pertuzumab In Her2-Positive Early Breast Cancer: Current Use And Perspectives
Eiger, D., Ponde, N. F., & de Azambuja, E. (2019) · Future Oncology · doi:10.2217/fon-2018-0896 · Cited by 18
FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: Today, Tomorrow, and Beyond
Hildebrandt, M. G., Lauridsen, J. F., Vogsen, M., Holm, J., Vilstrup, M. H., Braad, P., Gerke, O., Thomassen, M., Ewertz, M., & Høilund‐Carlsen, P. F. (2019) · Cancers · doi:10.3390/cancers11081190 · Cited by 17
Culyer, A. J. (2014) · Cited by 17
Novel targeted therapies for metastatic breast cancer
Jazieh, K., Bell, R., Agarwal, N., & Abraham, J. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.43 · Cited by 20
Chemotherapy use near the end-of-life in patients with metastatic breast cancer
Kessler, L. E., Sigfridsson, J., Hatzidaki, D., Bergh, J. C. S., Foukakis, T., Georgoulias, V., & Matikas, A. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05663-w · Cited by 19
Seligmann, J. F., Wright-Hughes, A. M., Pottinger, A., Velikova, G., Oughton, J. B., Murden, G., Rizwanullah, M., Price, C., Passant, H., Heudtlass, P., et al. (2020) · Clinical Oncology · doi:10.1016/j.clon.2020.06.003 · Cited by 17
Crespo, J., Sun, H., Wu, J., Ding, Q.-Q., Tang, G., Robinson, M. K., Chen, H., Şahin, A. A., & Lim, B. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241775 · Cited by 18
Yaegashi, M., Iwaya, T., Sasaki, N., Fujita, M., Ju, Z., Siwak, D. R., Hachiya, T., Sato, K. A., Endo, F., Kimura, T., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01266-4 · Cited by 20
Groen, E. J., van der Noordaa, M. E. M., Schaapveld, M., Sonke, G. S., Mann, R. M., van Ramshorst, M. S., Lips, E. H., Peeters, M.-J. T. F. D. V., van Duijnhoven, F. H., & Wesseling, J. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06235-2 · Cited by 19
Yan, Y., Cheng, X., Li, L., Zhang, R., Zhu, Y., Wu, Z., & Ding, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.669393 · Cited by 17
Gherghe, M., Lazăr, A. M., Mutuleanu, M.-D., Bordea, C. I., Ionescu, S. O., Mihăilă, R. I., Petroiu, C., & Stanciu, A. E. (2022) · Cancers · doi:10.3390/cancers15010207 · Cited by 17
Saibu, O. A., Singh, G., Sunday, O. A., Oluwafemi, A. T., Ajayi, T. M., Hammed, O. S., Oladipo, O. O., Odunitan, T. T., & Omoboyowa, D. A. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2175260 · Cited by 20
Hu, Z.-Y., Yan, M., Xiong, H., Ran, L., Zhong, J., Luo, T., Sun, T., Xie, N., Liu, L., Yang, X., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-02943-2 · Cited by 17
Poorvu, P. D., Vaz-Luís, I., Freedman, R. A., Lin, N., Barry, W. T., Winer, E. P., & Hassett, M. J. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4659-4 · Cited by 20
A Single Domain–Based Anti-Her2 Antibody Has Potent Antitumor Activities
Wu, X., Chen, S., Lin, L., Liu, J., Wang, Y., Li, Y., Li, Q., & Wang, Z. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.01.024 · Cited by 17
Yan, J., Xie, Y., Liu, Z., Yang, Y., & Zhou, T. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009636 · Cited by 19
Prevalence by therapy line and incidence of breast cancer brain metastases in 18 075 patients
Sammons, S. L., Sanglier, T., Leone, J. P., Erick, T. K., Lambert, P., Montemurro, F., Poppe, R., Restuccia, E., Tolaney, S. M., & Lin, N. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf048 · Cited by 18
Brenner, J. C., & Birkeland, A. C. (2015) · Medical Research Archives · doi:10.18103/mra.v0i3.77 · Cited by 18
Lee, H. J., Shin, S., Kang, J.-H., Han, K.-C., Kim, Y. H., Bae, J., & Park, K. H. (2020) · Cancers · doi:10.3390/cancers12092630 · Cited by 18
Biosimilars in an Era of Rising Oncology Treatment Options
Peeters, M., Planchard, D., Pegram, M. D., Gonçalves, J., Bocquet, F., & Jang, H. (2021) · Future Oncology · doi:10.2217/fon-2021-0546 · Cited by 19
Saito, A., Yoshida, H., Nishikawa, T., & Yonemori, K. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i10.868 · Cited by 18
Metastasis patterns and prognosis in young breast cancer patients: A SEER database analysis
Zhang, W., Wu, S., Liu, J., Zhang, X., Ma, X., Yang, C., Cao, M., Zhang, S., & Liu, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.872862 · Cited by 25
Ran, R., Ma, Y., Wang, H., Yang, J., & Jiao, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.975463 · Cited by 16
Rodriguez‐Perdigon, M., Haeni, L., Rothen‐Rutishauser, B., & Rüegg, C. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1159819 · Cited by 19
Hans, N., Gupta, S., Patel, A. K., Naik, S. N., & Malik, A. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.125950 · Cited by 16
Leung, H. W. C., Leung, J.-H., & Chan, A. L. F. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1394454 · Cited by 16
Fu, X., Zhang, Y., Yang, J., Qi, Y., Ming, Y., Sun, M., Shang, Y., Yang, Y., Zhu, X., & Gao, Q. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s174138 · Cited by 17
Tantiwetrueangdet, A., Panvichian, R., Wongwaisayawan, S., Sueangoen, N., & Lertsithichai, P. (2018) · Medical Oncology · doi:10.1007/s12032-018-1210-8 · Cited by 16
He, X., Ji, J., Tian, M., Esteva, F. J., Hortobágyi, G. N., & Yeung, S. J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0463 · Cited by 19
Kim, M. H., Kim, G. M., Kim, J. H., Kim, J. Y., Park, H. S., Park, S., Cho, Y. U., Park, B., Kim, S. I., & Sohn, J. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05505-4 · Cited by 16
Self-citationZhao, M., Lu, Y., Zhang, X., Wang, L., Tu, P., & Zeng, K. (2021) · Chemical Communications · doi:10.1039/d1cc00392e · Cited by 16
McBride, A., MacDonald, K., Fuentes‐Alburo, A., & Abraham, I. L. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2021.1928515 · Cited by 16
Ginzel, J. D., Acharya, C. R., Lubkov, V., Mori, H., Boone, P. G., Rochelle, L. K., Roberts, W. L., Everitt, J. I., Hartman, Z. C., Crosby, E. J., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0215 · Cited by 17
Luque, M., Sanz-Álvarez, M., Santamaría, A., Zazo, S., Cristóbal, I., de la Fuente, L., Mínguez, P., Eroles, P., Rovira, A., Albanell, J., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413297 · Cited by 20
Liu, W., & Han, Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-07565-x · Cited by 16
Latino, N. J., Galotti, M., Cherny, N. I., de Vries, E. G. E., Douillard, J.-Y., Kaidarova, D., & Ilbawi, A. (2022) · ESMO Open · doi:10.1016/j.esmoop.2021.100362 · Cited by 18
Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective
Ferrario, C., Christofides, A., Joy, A. A., Laing, K. E., Gelmon, K. A., & Brezden‐Masley, C. (2022) · Current Oncology · doi:10.3390/curroncol29040222 · Cited by 17
Drucker, A., Yoo, B. H., Khan, I. A., Choi, D., Montermini, L., Liu, X., Jovanović, S., Younis, T., & Rosen, K. V. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01342-2 · Cited by 16
CD52, CD22, CD26, EG5 and IGF-1R expression in thymic malignancies
Remón, J., Abedallaa, N., Clermont, E., Bluthgen, V., Lindsay, C. R., Besse, B., & de Montpréville, V. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.03.019 · Cited by 16
Moilanen, T., Mustanoja, S., Karihtala, P., & Koivunen, J. P. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000202 · Cited by 16
Lamble, A. J., Dietz, M. S., Laderas, T., McWeeney, S. K., & Lind, E. F. (2017) · Journal of Immunological Methods · doi:10.1016/j.jim.2017.11.010 · Cited by 17
Blanchette, P., Desautels, D. N., Pond, G. R., Bartlett, J., Nofech‐Mozes, S., Yaffe, M. J., & Pritchard, K. I. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4734-x · Cited by 16
Sim, S. H., Park, I. H., Jung, K. H., Kim, S., Ahn, J. H., Lee, K.-H., Im, S., Im, Y., Park, Y. H., Sohn, J., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0618-z · Cited by 18
Self-citationPharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy
Rocca, A., Andreis, D., Fedeli, A., Maltoni, R., Sarti, S., Cecconetto, L., Pietri, E., Schirone, A., Bravaccini, S., Serra, P., et al. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1078311 · Cited by 16
Major Strides in HER2 Blockade for Metastatic Breast Cancer
Sharma, P. (2020) · New England Journal of Medicine · doi:10.1056/nejme1916310 · Cited by 16
Heme Oxygenase-1 Inhibits Tumor Metastasis Mediated by Notch1 Pathway in Murine Mammary Carcinoma
Li, Q., Liu, Q., Cheng, W., Wei, H., Jiang, W., Fang, E., Yu, Y., Jin, J., & Zou, C. (2019) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504018x15415906335771 · Cited by 16
Huang, T., Yan, T., Chen, G., & Zhang, C. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.714639 · Cited by 15
Lander, E. M., Rappazzo, K. C., Huang, L., Hu, J., Chen, H., Shyr, Y., & Abramson, V. G. (2022) · The Oncologist · doi:10.1093/oncolo/oyac247 · Cited by 17
Zhou, M., Wang, S., Wan, N., Yuan, S., Hu, X., Zhou, W., Qing, B., Liu, M., Sun, W., Fan, P., et al. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-6054 · Cited by 17
Systemic treatments for breast cancer brain metastasis
Chen, Q., Xiong, J., Ma, Y., Wei, J., Liu, C., & Zhao, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1086821 · Cited by 19
Debets, D. O., Stecker, K. E., Piskopou, A., Liefaard, M. C., Wesseling, J., Sonke, G. S., Lips, E. H., & Altelaar, M. A. F. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101203 · Cited by 18
The Impact of HER2-Low Expression on Oncologic Outcomes in Hormone Receptor-Positive Breast Cancer
Park, W. K., Nam, S. J., Kim, S. W., Lee, J. E., Yu, J., Ryu, J. M., & Chae, B. J. (2023) · Cancers · doi:10.3390/cancers15225361 · Cited by 17
Self-citationCai, A., Chen, Y., Wang, L. S., Cusick, J., & Shi, Y. H. (2024) · Cancers · doi:10.3390/cancers16152635 · Cited by 15
Yamashita, T., Saji, S., Takano, T., Naito, Y., Tsuneizumi, M., Yoshimura, A., Takahashi, M., Tsurutani, J., Iwatani, T., Kitada, M., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01888 · Cited by 19
Ma, J., Wang, J., Xu, T., Ouyang, Q., Wang, X., Wang, J., Gan, L., Ouyang, Z., Lin, D., Sun, T., et al. (2025) · 癌症:英文版 · doi:10.1002/cac2.12662 · Cited by 15
Debbi, K., Benderra, M., Médioni, J., Durdux, C., To, N. H., Boukhobza, C., Grellier, N., Benmaziane, A., Monnier, L., Gligorov, J., et al. (2025) · The Breast · doi:10.1016/j.breast.2025.104421 · Cited by 15
Pertuzumab in gastrointestinal cancer
Oh, D., & Bang, Y. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1126578 · Cited by 15
Pool, M., de Boer, H. R., Hooge, M. N. L., van Vugt, M. A. T. M., & de Vries, E. G. E. (2017) · Theranostics · doi:10.7150/thno.17934 · Cited by 16
Diaby, V., Ali, A. A., Williams, K. J., Ezendu, K., Soto‐Pérez‐de‐Celis, E., Chávarri-Guerra, Y., & Lopes, G. D. L., Jr. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4473-4 · Cited by 16
Daniels, B. J., Kiely, B. E., Houssami, N., Lord, S. J., Dobbins, T., Lu, C. Y., Ward, R. L., & Pearson, S. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.405 · Cited by 15
Zakeri, K., Narayanan, D., Evans, G. J., Prasanna, P. G. S., Buchsbaum, J. C., Vikram, B., & Capala, J. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.214684 · Cited by 16
Shitara, K., Hara, H., Yoshikawa, T., Fujitani, K., Nishina, T., Hosokawa, A., Asakawa, T., Kawakami, S., & Muro, K. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01558-z · Cited by 15
Nogová, L., Mattonet, C., Scheffler, M., Taubert, M., Gardizi, M., Sos, M. L., Michels, S. Y. F., Fischer, R. N., Limburg, M., Abdulla, D. S. Y., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3131 · Cited by 16
Wang, C., Lin, Y., Zhou, Y., Mao, F., Zhu, H., Guan, J., Zhang, X., Shen, S., Huang, X., Chen, C., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07143-2 · Cited by 15
Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease
Mills, M. N., King, W., Soyano, A. E., Piña, Y., Czerniecki, B. J., Forsyth, P. A., Soliman, H. H., Han, H. S., & Ahmed, K. A. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-022-03977-x · Cited by 16
Molecular Biology of Breast Cancer
Aftimos, P. G., Azim, H. A., & Sotiriou, C. P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802761-5.00026-2 · Cited by 16
Norton, N., Fox, N., McCarl, C., Tenner, K., Ballman, K. V., Erskine, C. L., Necela, B. M., Northfelt, D., Tan, W. W., Calfa, C. J., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0989-8 · Cited by 15
Current Treatment Options for Breast Cancer Brain Metastases
Raghunath, A., Desai, K. B., & Ahluwalia, M. S. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0618-5 · Cited by 15
Asano, J., & Hirakawa, A. (2020) · Pharmaceutical Statistics · doi:10.1002/pst.2049 · Cited by 15
Yazaki, S., Hashimoto, J., Ogita, S., Nakano, E., Suzuki, K., & Yamauchi, T. (2020) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000939 · Cited by 15
Kedashiro, S., Kameyama, T., Mizutani, K., & Takai, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-86437-2 · Cited by 15
Cardio-oncology Related to Heart Failure
Kenigsberg, B. B., Jain, V., & Barac, A. (2017) · Heart Failure Clinics · doi:10.1016/j.hfc.2016.12.002 · Cited by 16
Questioning Our APHINITY for More
Miller, K. D. (2017) · New England Journal of Medicine · doi:10.1056/nejme1706150 · Cited by 15
Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach
Adesoye, T., Dumbrava, E. E. I., Raghav, K. P. S., Şahin, A. A., Chen, H., Lee, S. S., Javle, M. M., Pant, S., Alhalabi, O., Le, X., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1982 · Cited by 21
Iyengar, N. M., Smyth, L. M., Lake, D. E., Gucalp, A., Singh, J. C., Traina, T. A., DeFusco, P. A., Fornier, M. N., Goldfarb, S. B., Jhaveri, K. L., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.16211 · Cited by 14
Gonullu, B., Angeli, E., Pamoukdjian, F., & Bousquet, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043590 · Cited by 14
Current Management and Future Perspectives in Metastatic HER2-Positive Breast Cancer
Sánchez‐Lorenzo, L., Bachiller, A., Gea, C., & Espinós, J. (2023) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2023.151554 · Cited by 16
Systemic Therapies for HER2-Positive Advanced Breast Cancer
Angelis, V., & Okines, A. F. C. (2023) · Cancers · doi:10.3390/cancers16010023 · Cited by 16
Zhou, Y.-T., Chu, J., Zhao, S., Li, G.-L., Fu, Z., Zhang, S., Gao, X.-H., Ma, W., Shen, K., Gao, Y., et al. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01232-9 · Cited by 15
Liu, J., Zhu, T., Zhao, R., Ren, W., Zhao, F., & Liu, J. (2024) · Gastric Cancer · doi:10.1007/s10120-024-01478-6 · Cited by 16
Antoine, A., Pérol, D., Robain, M., Bachelot, T., Choquet, R., Jacot, W., Yahia, B. B. H., Grinda, T., Delaloge, S., Lasset, C., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115072 · Cited by 15
Yang, X., Yang, D., Xue, Q., Luo, X.-J., & Zhang, G. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1467033 · Cited by 16
Genetics of Pancreatic Cancer and Its Implications on Therapy
Tatarian, T., & Winter, J. M. (2016) · Surgical Clinics of North America · doi:10.1016/j.suc.2016.07.014 · Cited by 14
ErbB Proteins as Molecular Target of Dietary Phytochemicals in Malignant Diseases
Filippi, A., Ciolac, O.-A., Ganea, C., & Mocanu, M. (2017) · Journal of Oncology · doi:10.1155/2017/1532534 · Cited by 14
Targeted therapy for breast cancer in older patients
Ponde, N. F., Wildiers, H. P. M. W., Awada, A. H., de Azambuja, E., Deliens, C., & Lago, L. D. (2019) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2019.05.012 · Cited by 16
Genomics-Enabled Precision Medicine for Cancer
Roos, A., & Byron, S. A. (2019) · Cancer treatment and research · doi:10.1007/978-3-030-16391-4_5 · Cited by 14
Zucchetti, B. M., Nicolò, E., & Curigliano, G. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1638362 · Cited by 14
Modi, N. D., Tan, E., Rowland, A., Koczwara, B., Kichenadasse, G., McKinnon, R. A., Wiese, M. D., Sorich, M. J., & Hopkins, A. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01130 · Cited by 15
Rødland, M. S., Nikolaysen, F., Chitano, Y., & Stang, E. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15643 · Cited by 15
Cheng, L.-J., Loke, L., Lim, E. H., Pearce, F., Aziz, M. I. A., & Ng, K. (2021) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2021.1880323 · Cited by 14
Lv, H., Yan, M., & Jiang, Z. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211013326 · Cited by 14
Peptidomimetic-based antibody surrogate for HER2
Zheng, M., Li, C., Zhou, M., Jia, R., She, F., Wei, L., Cheng, F., Li, Q., Cai, J., & Wang, Y. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.04.016 · Cited by 16
Functional genomics for breast cancer drug target discovery
Yoshimaru, T., Nakamura, Y., & Katagiri, T. (2021) · Journal of Human Genetics · doi:10.1038/s10038-021-00962-6 · Cited by 15
New Treatments for Recurrent Uterine Cancer
Toboni, M. D., & Powell, M. A. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01129-4 · Cited by 17
Lee, Y., Lee, M., Kim, H.-S., Kim, J., Ahn, J. S., Im, Y., & Park, Y. H. (2022) · Cancer Research and Treatment · doi:10.4143/crt.2021.1103 · Cited by 16
Metadata
- Authors
- Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., Clark, E., Ross, G., Benyunes, M. C., & Cortés, J.
- Affiliations
- MedStar Washington Hospital Center (US)
- Asan Medical Center (KR)
- National Cancer Center (KR)
- Institute of Oncology NN Petrov (RU)
- Hospital Universitario 12 De Octubre (ES)
- Centre Antoine Lacassagne (FR)
- University Hospital Heidelberg (DE)
- Roche (United Kingdom) (GB)
- Genentech (US)
- Vall d'Hebron Hospital Universitari (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-02-19
- Volume
- 372
- Issue
- 8
- Pages
- 724-734
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5584549
- OpenAlex
- W2137228442
- Cited by
- 2,164
- References
- 26
- Citations by year
- 2026: 138 · 2025: 150 · 2024: 157 · 2023: 197 · 2022: 191 · 2021: 212 · 2020: 206 · 2019: 217 · 2018: 202 · 2017: 207 · 2016: 197 · 2015: 87
- FWCI
- 100.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Tampere University Institutional Repository (Tampere University) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Tampere University Institutional Repository (Tampere University) (submittedVersion)
- Funders
- F. Hoffmann-La Roche
- Genentech
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- pertuzumab, trastuzumab, docetaxel, HER2-positive breast cancer, metastatic breast cancer, overall survival, progression-free survival, duration of response, cardiac safety, HER2-targeted therapy, first-line chemotherapy
- MeSH terms
- Trastuzumab, Docetaxel, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Humans, Infusions, Intravenous, Middle Aged, Neoplasm Metastasis, Survival Analysis, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Taxoids, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.